<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <title>Athan Dial - Portfolio | Scaling AI-Driven Drug Nominations from 250 to 7,000 Compounds</title>
  <meta name="description" content="Built pipeline scaling compound nominations 26× while improving hit rates from 5% to 27% — phased rollout strategy balanced speed with quality gates">

  
  
    <meta property="og:image" content="https://athan-dial.github.io/img/profile.jpg" />
    <meta property="og:title" content="Athan Dial - Portfolio | Scaling AI-Driven Drug Nominations from 250 to 7,000 Compounds" />   
  
  <meta property="og:description" content="Built pipeline scaling compound nominations 26× while improving hit rates from 5% to 27% — phased rollout strategy balanced speed with quality gates" />
  <meta name="author" content="Athan Dial, PhD">
  
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.5.3/dist/css/bootstrap.min.css" integrity="sha384-TX8t27EcRE3e/ihU7zmQxVncDAy5uIKz4rEkgIXeMed4M0jlfIDPvg6uqKI2xXr2" crossorigin="anonymous">
  
  <link rel="preload" href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;0,800;1,300;1,400;1,600;1,700;1,800&family=Saira+Extra+Condensed:wght@100;200;300;400;500;600;700;800;900&display=swap" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;0,800;1,300;1,400;1,600;1,700;1,800&family=Saira+Extra+Condensed:wght@100;200;300;400;500;600;700;800;900&display=swap"></noscript>
  <link rel="preload" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.6.0/css/all.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.6.0/css/all.min.css"></noscript>
  <link rel="preload" href="https://cdn.jsdelivr.net/gh/devicons/devicon@latest/devicon.min.css" crossorigin="anonymous" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/devicons/devicon@latest/devicon.min.css" crossorigin="anonymous"></noscript>
  <link rel="preload" href="https://cdnjs.cloudflare.com/ajax/libs/simple-line-icons/2.5.5/css/simple-line-icons.min.css" integrity="sha512-QKC1UZ/ZHNgFzVKSAhV5v5j73eeL9EEN289eKAEFaAjgAiobVAnVv/AGuPbXsKl1dNoel3kNr6PYnSiTzVVBCw==" crossorigin="anonymous" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/simple-line-icons/2.5.5/css/simple-line-icons.min.css" integrity="sha512-QKC1UZ/ZHNgFzVKSAhV5v5j73eeL9EEN289eKAEFaAjgAiobVAnVv/AGuPbXsKl1dNoel3kNr6PYnSiTzVVBCw==" crossorigin="anonymous"></noscript>
  
  <link rel="preload" href="https://athan-dial.github.io/css/resume.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://athan-dial.github.io/css/resume.css"></noscript>
  <link rel="preload" href="https://athan-dial.github.io/css/tweaks.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://athan-dial.github.io/css/tweaks.css"></noscript>
  <link rel="preload" href="https://athan-dial.github.io/css/resume-override.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://athan-dial.github.io/css/resume-override.css"></noscript>
  <meta name="generator" content="Hugo 0.154.3">
  
   
  
</head>
<body id="page-top">
  <nav class="navbar navbar-expand-lg navbar-dark bg-primary fixed-top" id="sideNav">
  <a class="navbar-brand js-scroll-trigger" href="#page-top">
    <span class="d-block d-lg-none">Athan Dial, PhD</span>
    <span class="d-none d-lg-block">
      <img class="img-fluid img-profile rounded-circle mx-auto mb-2" src="/img/profile.jpg" alt="">
    </span>
  </a>
  <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
    <span class="navbar-toggler-icon"></span>
  </button>
  <div class="collapse navbar-collapse" id="navbarSupportedContent">
    <ul class="navbar-nav">
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#about">About</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#skills">Skills</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#tools">Tools</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#experience">Experience</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#education">Education</a>
      </li>
      
      
    </ul>
  </div>
</nav>
  <div class="container-fluid p-0">
    
<section class="resume-section p-3 p-lg-5 d-flex d-column" id="Scaling-AI-Driven-Drug-Nominations-from-250-to-7,000-Compounds">
  <div class="my-auto">
    <h1 class="mb-0"><span class="text-primary">Scaling AI-Driven Drug Nominations from 250 to 7,000 Compounds</span></h1>
    <h2 id="context">Context</h2>
<p>Early 2023 presented a defining challenge: Montai&rsquo;s AI models could predict activity across millions of compounds, but manual library creation processes were bottlenecked at ~250 compounds per program. The central question wasn&rsquo;t whether AI could generate predictions — it was whether we could build a scalable system that maintained scientific rigor while expanding the search space 20×.</p>
<p><strong>Facts:</strong></p>
<ul>
<li>Baseline: 100’s of compounds, chosen manually for screening from within existing library</li>
<li>Stakes: Scale 10× to 100× per program to enabled by bioactivity ML models</li>
<li>Environment: Early-stage biotech, unproven concept</li>
<li>My role: First data science/product hire, architected pipeline</li>
</ul>
<h2 id="the-challenge">The challenge</h2>
<blockquote>
<p>How do you architect a multi-objective decision system, that provides an optimal starting point for drug discovery funnels, is understandable by all the key decision-makers at the organization?</p>
</blockquote>
<p>This was a multi-faceted problem — ML scientists wanted maximum chemical diversity, medicinal chemists needed synthetic feasibility, and program leads to ensure they didn’t waste their team’s time on a batch of inactive compounds. Each stakeholder brought valid constraints — the pipeline needed to serve all groups while delivering high quality recommendations that would bolster confidence in the AI approach.</p>
<h2 id="the-solution">The solution</h2>
<p>I owned:</p>
<ul>
<li><strong>End-to-end ‘nomination’ pipeline architecture:</strong> Our team constructed an orchestrated SQL pipeline that enabled fully traceable, human-interpretable</li>
<li>ML integration strategy (model outputs → analytics)</li>
<li>Data quality framework for predictions</li>
<li>Phased rollout strategy (MVP → scale → quality)</li>
</ul>
<p>I influenced:</p>
<ul>
<li>Model selection criteria (with Duminda Ranasinghe, Lead ML Scientist)</li>
<li>Nomination criteria per program (with Jake Ombach, Computational Biologist)</li>
<li>External data partnerships (XtalPi, vendor libraries)</li>
</ul>
<h2 id="decision-frame">Decision Frame</h2>
<p><strong>Problem statement:</strong></p>
<p>Build a data pipeline that scales compound nominations 20× while maintaining or improving experimental hit rates, constrained by:</p>
<ul>
<li>Unproven AI prediction quality</li>
<li>Limited ML engineering capacity (small team)</li>
<li>Need for rapid learning cycles (not perfect first try)</li>
</ul>
<p><strong>Options considered:</strong></p>
<p><strong>Option A: Conservative scale (500-1000 nominations)</strong></p>
<ul>
<li>Pros: Lower risk, manageable if quality issues emerge</li>
<li>Cons: May miss opportunities in vast chemical space</li>
<li>Risk: Underutilize AI capability, slow learning</li>
</ul>
<p><strong>Option B: Aggressive scale (10,000+ immediately)</strong></p>
<ul>
<li>Pros: Maximum coverage of chemical space</li>
<li>Cons: Drowning in low-quality candidates, scientist overload</li>
<li>Risk: Lost trust if hit rate crashes, wasted experimental capacity</li>
</ul>
<p><strong>Option C: Phased scaling with quality gates</strong></p>
<ul>
<li>Pros: Learn at each phase, adjust criteria, build confidence</li>
<li>Cons: More complex coordination, requires patience</li>
<li>Risk: Slower initial progress</li>
</ul>
<p><strong>Decision:</strong> Chose Option C because:</p>
<p>[FACTS from archaeology p.20-21:]</p>
<ol>
<li>Phase 1 (2023): Baseline nomination (prove concept with known compounds)</li>
<li>Phase 2 (2024): Expand to 1000+ (maximize learning via generative + commercial)</li>
<li>Phase 3 (late 2024): Quality filters (diversity, confidence thresholds)</li>
</ol>
<p>Sequencing logic: Prove → scale → refine (not perfect upfront)</p>
<p><strong>Constraints:</strong></p>
<ul>
<li>Pipeline latency: Manual processes took 2-3 days → needed automation</li>
<li>Data volume: 10M compounds (2023) → 258M predictions (2024)</li>
<li>Team capacity: Solo data lead initially, growing to 5-6 by 2024</li>
</ul>
<h2 id="outcome">Outcome</h2>
<p><strong>Primary outcome:</strong></p>
<p>Scaled from 250 → 6,500+ nominations per program (26× increase) while IMPROVING hit-to-lead rates:</p>
<ul>
<li>TNFR1: 27% hit-to-lead (vs ~5% baseline)</li>
<li>Multiple programs advanced to lead optimization faster</li>
</ul>
<p>The significance: This wasn&rsquo;t just volume scaling — quality improved alongside throughput. By implementing phased quality gates and leveraging diverse data sources (generative models, commercial libraries, XtalPi partnerships), we validated that AI-driven discovery could outperform manual selection. This became Montai&rsquo;s core operational advantage and a key narrative for fundraising.</p>
<p><strong>Metrics:</strong></p>
<ul>
<li>Nomination throughput: 250 → 5,000-7,000 per program (Q4 2024)</li>
<li>Hit-to-lead conversion: 5% → 15-30% range</li>
<li>Pipeline latency: 2-3 days → same-day updates</li>
<li>Model predictions: 10M → 258M compounds scored</li>
</ul>
<p><strong>Guardrails maintained:</strong></p>
<ul>
<li>Nomination quality didn&rsquo;t degrade with scale (improved filters offset volume)</li>
<li>Scientist time per compound review stayed manageable (self-service dashboards)</li>
<li>Data infrastructure handled 10× load increase without major incidents (until STAT6 - separate case)</li>
</ul>
<p><strong>Second-order effects:</strong></p>
<ul>
<li>Enabled XtalPi partnership analysis (build vs buy decision)</li>
<li>Created reusable pipeline for future programs (MARS, cACN v2/v3)</li>
<li>Demonstrated industrialized discovery to investors (fundraising narrative)</li>
</ul>
<p><strong>Limitations acknowledged:</strong></p>
<ul>
<li>Diminishing returns emerged at ~5K nominations (quality &gt; quantity phase needed)</li>
<li>Generated Anthrologs initially unusable (separate failure/pivot story)</li>
<li>Pipeline automation never fully complete (some manual triggers remained)</li>
</ul>
<h2 id="reflection">Reflection</h2>
<p><strong>What I&rsquo;d do differently:</strong></p>
<p>Looking back at the archaeology of this work, three decisions stand out as suboptimal:</p>
<ul>
<li>Start with tighter nomination criteria earlier (wasted effort on low-probability compounds in Phase 2)</li>
<li>Invest in monitoring infrastructure upfront (reactive vs proactive on data quality)</li>
<li>Engage chemists more in generative model development (synthetic feasibility blindspot)</li>
</ul>
<p>The first two were classic &ldquo;move fast and learn&rdquo; tradeoffs that proved correct in hindsight — we needed the volume data to understand quality needs. The third was a genuine miss: treating synthetic feasibility as a post-generation filter rather than baking it into model training cost us months.</p>
<p><strong>What this taught me about decision-making:</strong></p>
<p>Three principles emerged that I&rsquo;ve since applied consistently:</p>
<ul>
<li>Phased rollouts with learning gates beat perfect upfront design — you can&rsquo;t architect your way out of uncertainty, you build to learn</li>
<li>Volume metrics mislead without quality tracking — nomination count was a vanity metric until we paired it with hit-to-lead conversion</li>
<li>Stakeholder confidence requires visible iteration — scientists trusted the pipeline because they saw us adjust criteria based on their feedback, not because the first version was perfect</li>
</ul>
<p><strong>How this informs future decisions:</strong></p>
<p>These lessons directly shaped my approach to subsequent projects:</p>
<ul>
<li>Always define success criteria per phase before executing — the Learning Agenda framework codified this</li>
<li>Build quality frameworks alongside feature development, not after crises — the STAT6 incident reinforced this</li>
<li>Balance exploration (maximize learning) with exploitation (optimize known strategies) — this framing now guides my portfolio thinking</li>
</ul>
<hr>
<p><strong>Factual Evidence Citations:</strong></p>
<ul>
<li>Drug Project Overviews.xlsx (nomination counts per program)</li>
<li>2024 Mid-Year Review (pipeline automation goals)</li>
<li>Quantitative Outcomes Inventory p.30 (metrics table)</li>
<li>Product Strategy case study p.20-21 (phasing logic)</li>
</ul>

  </div>
</section>

    <section><span style="color: #999999;">Nifty <a href="https://codepen.io/wbeeftink/pen/dIaDH">tech tag lists</a> from <a class="pen-owner-link" href="https://codepen.io/wbeeftink">Wouter Beeftink</a> </span>
      
    </section>
  </div>
  
  <script src="https://code.jquery.com/jquery-3.6.4.slim.min.js" integrity="sha256-a2yjHM4jnF9f54xUQakjZGaqYs/V1CYvWpoqZzC2/Bw=" crossorigin="anonymous"></script>
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.5.3/dist/js/bootstrap.bundle.min.js" integrity="sha384-ho+j7jyWK8fNQe+A12Hb8AhRq26LrZ/JpcUGGOn+Y7RsweNrtN/tE3MoK7ZeZDyx" crossorigin="anonymous"></script>
  
  <script src="https://unpkg.com/smoothscroll-polyfill@0.4.4/dist/smoothscroll.min.js" integrity="sha384-EYn4rWu1DHvYD0sSSSbMEtXQmMl58CFJd897806+RT1jJVYbhuZlZMN6yG9nCyFa" crossorigin="anonymous"></script>
  <script src="https://unpkg.com/smoothscroll-anchor-polyfill@1.3.2/dist/index.min.js" integrity="sha384-EY9NBEHCFbZANmPcTm7CgG8OhsFILy0VBLG85pF6OIpP42NVbZVNsFOc23PYTCkB" crossorigin="anonymous"></script>
  
  <script async src="/js/resume.js"></script>
  

  

  
</body>
</html>
